Portal de Periódicos da CAPES

A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model

2020; Nature Portfolio; Volume: 6; Issue: 2 Linguagem: Inglês

10.1038/s41564-020-00815-6

2058-5276

David W. Hawman, Gustaf Ahlén, K. Sofia Appelberg, Kimberly Meade‐White, Patrick W. Hanley, Dana Scott, Vanessa Monteil, Stéphanie Devignot, Atsushi Okumura, Friedemann Weber, Heinz Feldmann, Matti Sällberg, Alì Mirazimi,

Vector-Borne Animal Diseases

There is currently no specific prophylaxis or vaccine against Crimean-Congo haemorrhagic fever virus (CCHFV). Crimean-Congo haemorrhagic fever (CCHF) is a severe febrile illness transmitted by Hyalomma ticks in endemic areas, handling of infected livestock or care of infected patients. We report here the successful protection against CCHFV-mediated disease in a non-human primate disease model. Cynomolgus macaques were vaccinated with a DNA-based vaccine using in vivo electroporation-assisted delivery. The vaccine contained two plasmids encoding the glycoprotein precursor (GPC) and the nucleoprotein (NP) of CCHFV. Animals received three vaccinations and we recorded potent antibody and T cell responses after vaccination. While all sham-vaccinated animals developed viraemia, high tissue viral loads and CCHF-induced disease, the NP + GPC vaccinated animals were significantly protected. In conclusion, this is evidence of a vaccine that can protect against CCHFV-induced disease in a non-human primate model. This supports clinical development of the vaccine to protect groups at risk for contracting the infection. A DNA-based vaccine elicits humoral and cellular immunity and provides protection against Crimean-Congo haemorrhagic fever virus-mediated disease in a non-human primate model.